INTRODUCTION
Exercise is a significant component of primary cancer prevention and for improving the health and well-being of cancer survivors after treatment. In addition, there is a growing body of evidence that post–cancer treatment exercise reduces the risk of recurrence and increases longevity (1). Accordingly, exercise guidelines that reduce the risk of developing cancer have been established (2), and exercise guidelines after cancer treatment have primarily been developed over the last two decades (1). The 2019 ACSM consensus statement on exercise guidelines for cancer survivors provides an excellent review of “evidence-based guidelines for exercise testing, prescription, and delivery in cancer survivors” and should be considered a must read. In general, there is moderate to strong evidence that exercise after treatment is well tolerated, safe, and improves physical and mental well-being in cancer survivors (1).
The goal of exercise programming for cancer survivors is to improve physical fitness, physical functioning, quality of life, and cancer-related fatigue through individualized exercise plans (1). As an individual’s response to cancer and cancer treatment is unique, there may be survivors who are unable to tolerate minimal levels of exercise while there also may be a select population of cancer survivors who are able to tolerate a more aggressive approach to rehabilitation. Therefore, defining the optimal exercise load for a cancer survivor who has completed treatment has remained elusive, in part due to the many independent variables associated with health that are adversely affected by cancer. These late and long-term effects are presented in Table 1.
TABLE 1 -
Late and Long-Term Effects of
Cancer Treatment Where Physical Activity Can Have a Positive Impact
Cancer Treatment
|
Physical Changes
|
|
Surgery |
↓ |
Pulmonary function |
Radiation |
↓ |
Cardiac function |
Chemotherapy |
↓ |
Muscle mass |
Immunotherapy |
↑ |
Fat mass |
Hormone therapy |
↑ |
Body weight or body mass index |
Steroid therapy |
↓ |
Muscle strength/power |
|
↑ |
Inflammation |
|
↓ |
Immune function |
|
↓ |
Bone health |
|
↑ |
Trauma and scarring |
|
↑ |
Lymphedema |
|
Psychological and behavioral changes
|
|
↓ |
Exercise/physical activity |
|
↑ |
Physical symptom and pain |
|
↑ |
Depression |
|
↓ |
Cognitive function |
|
↓ |
Quality of life (multiple domains) |
There is emerging evidence in exercise oncology that manipulating the duration and intensity of exercise sessions may be a time-effective strategy in improving the clinical outcomes of cancer survivors. It is therefore the purpose of this article to review the efficacy and safety of implementing high-intensity interval training (HIIT) for cancer survivors and to provide the reader/practitioner practical advice when constructing HIIT exercise prescriptions for this group.
Herein, we define cancer survivors as individuals 18 years and older and include all cancer types, stages of diagnosis, and individuals who have undergone any one or combination of treatments, including surgery, hormonal therapy, chemotherapy, radiotherapy, and adjuvant therapy. Emerging data on the effectiveness of exercise training during treatment (e.g., chemotherapy) are forthcoming, yet at this time, they are insufficient to make recommendations and are excluded from this discussion.
Efficacy of Exercise for Cancer Survivors
According to the evidence-based recommendations found in the 2019 ACSM consensus statement on exercise guidelines for cancer survivors, “based on the current literature, an effective exercise prescription that most consistently addresses health-related outcomes experienced due to a cancer diagnosis and cancer treatment includes moderate-intensity aerobic training at least three times per week, for at least 30 minutes, for at least 8 to 12 wk. The addition of resistance training to aerobic training, at least two times per week, using at least two sets of 8 to 15 repetitions at least 60% of one repetition maximum, appears to result in similar benefits” (1, p. 2385). The recommendations did not include specifics with regards to HIIT training as the evidence to evaluate randomized controlled trials of low- and high-intensity exercise was insufficient.
;)
There is emerging evidence that the addition of HIIT may be beneficial for cancer survivors (3–5). In general, these collective papers indicated that HIIT was superior to usual care in improving aerobic capacity (V˙O2peak) but not superior to participating in moderate-intensity aerobic exercise. Mugele et al. (3) further concluded that there was no difference between HIIT compared with moderate-intensity aerobic training for changes in cardiorespiratory fitness, lean mass, and patient-reported outcomes. However, the general consensus was that HIIT may be a time-efficient mode of training for cancer survivors at any point during or after treatment (4). This is an important consideration as time is often cited as a significant barrier to exercise participation (6).
Training Programs
In addition to the reviews mentioned above, additional observational studies that detail duration, intensity, and efficacy of HIIT exercise for cancer survivors were reviewed for this article and are presented in Table 2.
TABLE 2 -
Summary of Selected Studies on HIIT, Including Age Range,
Exercise Prescription, Outcome Measures, and Safety
Study |
Entity |
Sample |
Training Duration/Frequency |
Exercise Rx |
Outcomes |
Safety |
Adamsen et al. (7) |
Various cancers |
M/F, n = 269, mean = 47 |
6 weeks, 9 hours/week |
HIIT: 30-minute WU, 45-minute resistance, 15-minute CV; resistance: 3 × 5–8 reps at 70%–100% 1RM; CV: cycle at 85%–95% HRmax
|
Decrease in fatigue; increase in leg press |
No adverse events; adherence = 70.8% |
Klika et al. (8) |
Various cancers |
Females, 41; Males, 13; N = 54; mean = 53.8 ± 10.3 years |
12 weeks, 5× per week |
Intervals at 100%–115%; LT = 24% of the time |
Increase in V˙O2max by 5% males, 14% females; females: decrease in BMI, percentage fat down, peak power, threshold power, heart rate max lower; males: PPO up, PP, PTlact up, no change in body comp |
No adverse events |
van Waart et al. (9) |
Breast and colon |
N = 230 (228 females), mean = 50. 7 ± 9.1 |
2× week till end of chemotherapy |
UC, low intensity and moderate to high intensity; JIIT included 2 × 8 RM and 30 minutes of aerobic activity at 50%–80% max workload |
Increased peak O2 uptake, strength, fatigue, and chemotherapy completion rate |
48%–71% compliancy for all three groups |
Edvardsen et al. (10) |
Lung |
Females, 33; Males, 28; RCT, N = 61 |
20 weeks, 3× per week |
Walking uphill at 80%–95% of HRmax and 3 × 6–12 RM |
Increases in 1-RM, peak O2 uptake, chair stand, muscle mass, QoL |
Adherence = 88% |
Heinrich et al. (11) |
Various cancers |
Females, 6; Males, 2; N = 8; mean 53.5 ± 5.0 |
5 weeks, 3× per week, 60 minutes |
HIFT: session based on CrossFit template (e.g., rowing, running, or jumping rope), gymnastic (e.g., push-ups, squats, or pull-ups), and weightlifting (e.g., presses, deadlifts, and kettlebell swings) exercises and were scaled as necessary |
Increased emotional function, FFM increase, FM decrease, decreased body fat 4.7%, increased balance, lower body strength, power, aerobic capacity, and endurance |
Adherence = 75% |
Schmitt et al. (12) |
Breast |
Female, N = 26 |
3 weeks; LMIE: 6× per week, 75-minute session; HIIT: 3× per week, ~27 minutes |
LMIE: 60 minutes walking outdoors, 15 minutes cycling indoors at 60% HRpeak; HIIT: 5-minute warm-up at 70% HRpeak, 8 × 1-minute intervals at >95% HRpeak, 2-minute slow walking between intervals; 24-hour rest between sessions |
Both groups improved work economy and QOL while decreasing fatigue; LMIE: improved peak O2, muscle mass, and FFM; HIIT: improved peak O2 greater than LMIE; decrease in total body fat mass |
No adverse events |
Toohey et al. (13) |
Various
cancers |
Female, N = 16, mean = 51.6 ± 13.01 years |
12 weeks, 36 sessions |
CLMIT: 20 minutes continuous at ≤55% maximal heart rate, 5-minute warm-up and cool-down; LVHIIT: ≥85% maximal heart rate, 5-minute warmup/cool-down; 7 × 30-second intervals; 1-minute rest between intervals; *progressed to 7 intervals by session 5 |
Both interventions improve QoL, functional capacity, and select CVD risk factors; LVHITT: increase in 6MWT distance |
No adverse events |
Toohey et al. (4) |
Various cancers |
Female, N = 16, mean = 51.6 ± 13.01 years |
12 weeks, 36 sessions |
CLMIT: 20 minutes continuous at ≤55% maximal heart rate, 5-minute warm-up and cool-down; LVHIIT: ≥85% maximal heart rate, 5-minute warm-up/cool-down; 7×30-second intervals; 1-minute rest between intervals; *progressed to 7 intervals by session 5 |
Both interventions improve QoL, functional capacity, and select CVD risk factors; LVHITT: increase in 6MWT distance |
No adverse events |
Adams et al. (14) |
Testicular |
N = 63, mean = 43.7 ± 10.8 |
12 weeks, 3× per week |
4 × 4 minutes with 3 minutes between intervals at 75%–95% V˙O2peak
|
Increased V˙O2peak and decreases in CAD risk factors |
Adherence = 99% |
Mijwel et al. (15) |
Breast |
Female, N = 240, mean = 52–54 years |
16 weeks, 2× per week |
Resistance: 2–3 sets × 8–12 reps at 70% estimated 1RM, progressed to 80% 1RM; aerobic: 3 × 3-minute intervals of HIIT exercise on cycle ergometer, RPE of 16–18; 1-minute recovery between bouts at low intensity |
HIIT: prevented increase in fatigue compared with UC; decrease in symptom burden during treatment; increase in role functioning |
No adverse events; adherence: RT, 75%; AT, 83% |
Kampshoff et al. (16) |
Various cancers |
M/F, N = 277, mean = 54 years |
12 weeks |
Resistance: 6 exercises, 2 sets × 10 reps, HI = 70%–85% 1RM, LMI = 40%–55% 1RM; endurance interval (part A): 8-minute alternating workload (MSEC), 60 seconds recovery at 30%, HI = 30 seconds at 65%, LMI = 30 seconds at 45%; endurance intervals (part B): 3 × 5-minute constant workload; HRR: HI ≥ 80%, LMI = 40%–50% |
Both HI and LMI improved peakV˙O2 and fatigue compared with WLC |
No adverse events |
Lee et al. (17) |
Breast |
Female, N = 30, mean = 46.9 ± 9.8 years |
8 weeks, 3× per week, 30 minutes |
7 × 1-minute intervals at 90% PPO; 2-minute RBIs at 10% PPO |
No change in V˙O2 in intervention but decreased V˙O2max in the control group |
No adverse events; adherence = 82.3% |
Devin et al. (18) |
Colorectal |
M/F, N = 47, mean = 61 |
4 weeks, 3× per week |
Cycle ergometry; MIE, 50 minutes at 50%–70% HRpeak; HIE, 10-minute warm-up at 50%–70% HRpeak; 4 × 4 min bouts at 85%–95% HRpeak; 3-minute recovery at 50%–70% HRpeak
|
HIE: significantly increased V˙O2peak and lean body mass; significant decrease in fat mass and percent fat; MIE: no significant changes; both: significant increase in PPO |
No adverse events; some aggravate on of sciatica and knee pain with HIE |
CVD, cardiovascular disease; HR, heart rate; MIE, moderate-intensity exercise; RPE, rating of perceived exertion; RM, repetition maximum; PPO, peak power output; QoL, quality of life; RBI, rest between intervals.
Based on the summary data in Table 2, on average, the research has shown that using high-intensity exercise in cancer survivors increases aerobic capacity (V˙O2peak), peak power output, and quality of life. For the selected studies, favorable body composition changes after HIIT are equivocal, most likely as a result of the relatively short training periods (4 to 12 weeks). The data presented indicate relatively few adverse events after HIIT training, and adherence rates of ~70%–99%.
From the summary data, frequency of interval training appears to be optimal at 2 or 3 sessions per week, but this is highly dependent on the initial fitness level. Intensity levels of HIIT are variable but generally in agreement with the definition of HIIT of 80%–100% of peak heart rate. An important note here is that peak heart rate after cancer treatment in an untrained individual is most likely lower than age-predicted maximal heart rate or a true maximal heart. This creates a situation whereby the “high” intensity level for a cancer survivor HIIT program may be relatively low compared with HIIT training programs for a healthy individual.
Most exercise oncology HIIT studies have used treadmill walking or running or cycle ergometry as a mode of exercise during the training sessions. On average, individual training sessions in the studies presented ranged from 45 to 90 minutes. Most studies reviewed did not detail exercise progression. The totality of the data on HIIT for cancer survivors is small and generally appears safe for cancer survivors, but making assumptions that HIIT is safe for all cancer survivors is not advised.
Risks and Contraindications for Exercise Training for Cancer Survivors
Cancer and cancer treatment create an enormous emotional, physical, and financial burden for most survivors. As a result, survivors nearer to the end of treatment are most likely deconditioned and emotionally fatigued. It is recommended that exercise trainers working with cancer survivors have a solid understanding of the contraindications to exercise testing and training and be able to recognize the signs and symptoms of changes in health status. These are presented in Table 3.
TABLE 3 -
Contraindications and Precautions to
Exercise Testing and Training for Patients with
Cancer
|
Contraindications to Exercise Testing and Training |
Precautions Requiring Modification and/or Physician Approval |
Factors related to cancer treatment |
No exercise on days of intravenous chemotherapy (recommendation changing) |
Caution if on treatments that affect the lung and/or heart: recommend medically supervised exercise testing and training |
No exercise before blood draw |
Mouth sores/ulcerations: avoid mouthpiece for maximal testing: use face mask |
Severe tissue reaction to radiation therapy |
Lymphedema: wear appropriate compression garments |
Hematologic |
Platelet count <50,000 |
Platelets >50,000–150,000: avoid tests or exercise (contact sports) that increase risk of bleeding |
Hemoglobin level <10.0 g/dL |
White blood cells >3,000-4,000: ensure proper sterilization of equipment |
Absolute neutrophil count <0.5 × 109/L |
Hemoglobin >10 g/dL to 11.5–13.5 g/dL: caution with maximal tests |
|
Avoid activities that may increase the risk of bacterial infection (swimming) |
Musculoskeletal |
Extreme fatigue/muscle weakness |
Any pain or cramping: investigate |
Bone, back, or neck pain |
Osteopenia: avoid high-impact exercise if risk of fracture |
Severe cachexia (loss of >35% premorbid weight) |
Loss of muscle mass limits exercise to mild intensity |
Karnofsky performance status score <60%; poor functional status: avoid exercise testing |
Cachexia: multidisciplinary approach to exercise |
Systemic |
Acute infections |
May indicate systemic infection and should be investigated; avoid high-intensity exercise |
Febrile illness: fever >100 F |
Avoid exercise until asymptomatic for >48 hours |
General malaise |
|
Gastrointestinal |
Severe nausea |
Compromised fluid and/or food intake: recommend multidisciplinary approach/consultation with nutritionist |
|
Dehydration |
Ensure adequate nutrition with electrolyte drinks and water (avoid hyponatremia) |
Vomiting or diarrhea within 24–36 hours |
|
Poor nutrition: inadequate fluid and/or intake |
|
Cardiovascular |
Chest pain |
Exercise is contraindicated (refer to physician) |
Resting HR >100 BPM or <50 BPM |
Caution: recommend medically supervised exercise testing and training |
Resting SBP >145 mmHg and/or DBP >95 mmHg |
|
Resting SBP <85 mmHg |
|
Irregular HR |
Exercise is contraindicated (refer to physician) |
Swelling of ankles |
Lymphedema: wear appropriate compression garments |
Pulmonary |
Dyspnea |
Mild to moderate dyspnea: avoid maximal tests |
Cough, wheezing |
Avoid activities that require significant oxygen transport (high-intensity X) |
Chest pain increased by deep breath |
|
Neurologic |
Ataxia/dizziness/peripheral sensory neuropathy |
Avoid activities that require significant balance and coordination (treadmill) |
Significant decline in cognitive performance |
Ensure patient is able to understand and follow instructions |
Disorientation |
Use well-supported positions for exercise |
Blurred vision |
|
Adapted from McNeely
et al. (
15).
When there is doubt about the survivor’s health status or a decline in physical functioning, the exercise specialist should refer their clients to their primary care physician or oncologist for further evaluation or clearance to continue with the exercise program.
Practical Advice
Medical History
When prescribing exercise for cancer survivors, a careful review of an extensive medical and cancer history (including stage based on TNM status, treatment including all drugs, radiation treatment [dose and time course], surgery, and any adjuvant therapy) is required (19,20). In addition, because cancer is typically a disease of older individuals, comorbidities, such as cardiovascular, pulmonary disease, and diabetes, should be evaluated and appropriate precautions taken to ensure survivor safety.
Monitoring
It is important to monitor hematologic abnormalities, and it is recommended that cancer survivor assessment includes complete blood counts, physical assessment (cardiovascular health, muscular strength and endurance, balance/coordination, body composition, and range of motion), and quality of life assessment (1). Clinical assessments may include pulmonary function testing to evaluate potential pulmonary fibrosis, heart function assessed by echocardiography to detect subclinical cardiomyopathy, neurologic examination to assess the severity of chemotherapy-induced peripheral neuropathy and pain, and a DXA scan to evaluate bone mineral density (21). Physician (oncologist or primary care) assent should be obtained for all cancer patients starting an exercise program that includes vigorous exercise intensity.
Sidebar: Definitions
Cancer — A term for diseases in which abnormal cells divide without control and can invade nearby tissues. Carcinoma is a cancer that begins in the skin or in tissues that line or cover internal organs. Sarcoma is a cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a cancer that begins in blood-forming tissue, such as the bone marrow, and causes too many abnormal blood cells to be made. Lymphoma and multiple myeloma are cancers that begin in the cells of the immune system. Central nervous system cancers are cancers that begin in the tissues of the brain and spinal cord.
Cancer survivor — A person is considered to be a survivor from the time of diagnosis until the end of life.
Cancer survival rate — The survival rate is often stated as a 5-year survival rate, which is the percentage of people in a study or treatment group who are alive 5 years after their diagnosis or the start of treatment.
Exercise oncology — evaluation of physical activity on cancer treatment and prognosis
Exercise prescription
Individualized exercise prescriptions for cancer survivors should address all components of fitness based on the recommendations from the 2019 ACSM consensus statement on exercise guidelines for cancer survivors (1). However, cardiovascular conditioning should be a focus of the training plan for cancer survivors as there is a clear relationship between cardiorespiratory fitness and decreased mortality in this group (22).
In general, the classification of aerobic fitness based on cancer survivor–specific V˙O2peak values are typically well below healthy age-matched peers and therefore would be considered “poor.” Low aerobic fitness due to complications from cancer treatment may require physical therapy and modification to the exercise prescription. Regardless, aerobic training for all fitness levels should be incorporated at least three times per week for ~30 minutes at low to moderate intensity for 8 to 12 weeks at the beginning phase of rehabilitation. This time allows for the evaluation of heart rate and blood pressure responses to exercise and to gauge whether an individual has the endurance capacity to complete future 30- to 60-minute aerobic sessions. In general, the cancer survivor should be able to complete 30 minutes of continuous exercise in a single session before starting HIIT.
After a general aerobic base training of 2 to 3 months, HIIT sessions can then be incorporated into the exercise program. HIIT can be prescribed twice per week with approximately 48 hours between each HIIT session with each session 30 to 60 minutes in duration. Each session should consist of a dynamic warm-up of 5 to 10 minutes at low to moderate intensity, followed by the interval conditioning phase of the session and culminating with a 10-minute cool-down period and/or stretching.
The intensity of the interval should be based on a percentage of peak heart rate (measured), V˙O2peak (measured), or heart rate reserve whereby maximal heart rate is measured rather than estimated. Ranges for effective interval intensity are from 80% to 100% of peak heart rate (measured), 60% to 90% heart rate reserve when maximal heart rate and resting heart are available, and 60% to 90% of V˙O2peak (measured). Rating of perceived exertion has been used effectively to prescribe exercise intensity and should be between 7 and 9 on a modified Borg CR-10 scale or between 14 and 17 on the original 6 to 20 scale.
The number of intervals in a session is dependent on the work-to-rest ratio, and in the literature, it ranges from 15- and 30-second sprint intervals to 1-, 2-, 3-, 4-, and 5-minute high-intensity intervals followed by 1 to 3 minutes of recovery between repetitions. Superior increases in aerobic capacity were seen with programs consisting of 4 × 4-minute intervals with a 3-minute rest between repetitions (14,18).
The rate of progression is based on client fitness, training response, and individual goals. Progression for interval training can include increasing the number of intervals and/or decreasing the rest duration and increasing the length of each interval. Progression volume should not exceed 10% in the subsequent week to minimize risk of injury, muscle soreness, undue fatigue and long-term risk of overtraining (23). This is especially a concern if the cancer survivor is anemic or has low red blood cell counts (Table 4).
TABLE 4 -
Summary of HIIT for
Cancer Survivors after an 8- to 12-wk Aerobic Base Conditioning Program
Frequency |
2× per Week |
Minimum 48 Hours between Sessions |
|
|
Intensity |
80%–100% HRpeak
|
60%–90% HRreserve
|
60%–90% V˙O2peak
|
|
Time (total) |
30–60 minutes |
Dynamic warm up 5 minutes |
Interval session (variable set and reps) |
Cool-down 5–10 minutes |
Type |
Treadmill walking (inclined) |
Jogging/running |
Stationary cycling |
|
Volume |
1–4 sets |
2–4 minutes duration |
~3-minute rest between intervals or sets |
|
Progression |
≤10% increase in volume from previous week |
|
|
|
Precautions
Client safety is crucial when working with cancer patients who may have compromised immune systems, subclinical cardiomyopathy, and other comorbidities. Practitioners should monitor heart rate, blood pressure, and if available, oxygen saturation, during a client’s first HIIT session to ensure appropriate hemodynamic response to exercise. Clients should be instructed to decrease and/or stop the workload if they are dizzy, are ataxic, have chest pain, and/or have serious difficulty breathing. Appropriate emergency equipment, including oxygen, should be available for cancer patients who are exercising in a commercial setting.
Future Research
Exercise oncology has produced tremendous advances in exercise programming for cancer survivors. Through trial and error, observation, and a limited number of randomized controlled exercise training studies, evidence is moderate to strong that exercise is both beneficial and safe for cancer survivors after treatment. Advances in the dosing of exercise and addition of strategies such as HIIT show promise and should be considered as part of a practitioner’s approach to exercise prescription. For researchers working in exercise oncology, reporting the dose of exercise used in interventional studies should clearly address frequency, intensity, time, type, volume, and progression (FITT-VP principle). Other areas of interest in exercise oncology include prehabilitation strategies (19,24) to increase fitness before chemotherapy treatment and exercise training during chemotherapy infusion.
BRIDGING THE GAP
Based on the currently available evidence, HIIT training is safe, tolerable, and effective as part of a comprehensive cancer rehabilitation program. Cancer survivors who are relatively healthy after treatment can add vigorous intensity to their rehabilitation/training programs to be time efficient. An extensive medical and cancer history and physician clearance should be obtained before prescribing HIIT training to your clients.
References
1. Campbell KL, Winters-Stone KM, Wiskemann J, et al.
Exercise guidelines for
cancer survivors: consensus statement from international multidisciplinary roundtable.
Med Sci Sports Exerc. 2019;51(11):2375–90.
2. U.S. Department of Health and Human Services.
Physical Activity Guidelines for Americans. Washington (DC): Department of Health and Human Services; 2008. [cited 2021 May 4]. Available from:
https://health.gov/our-work/physical-activity/previous-guidelines/2008-physical-activity-guidelines.
3. Mugele H, Freitag N, Wilhelmi J, et al. High-intensity
interval training in the therapy and aftercare of
cancer patients: a systematic review with meta-analysis.
J Cancer Surviv. 2019;13:205–23.
4. Toohey K, Pumpa K, McKune A, Cooke J, Semple S. High-intensity
exercise interventions in
cancer survivors: a systematic review exploring the impact on health outcomes.
J Cancer Res Clin Oncol. 2018;144(1):1–12.
http://dx.doi.org.ezproxy.uindy.edu/10.1007/s00432-017-2552-x.
5. Wallen MP, Hennessy D, Brown S, et al. High-intensity
interval training improves
cardiorespiratory fitness in
cancer patients and survivors: a meta-analysis.
Eur J Cancer Care. 2020;29:e13267. https://doi.org/10.1111/ecc.13267.
6. Herazo-Beltrán Y, Pinillos Y, Vidarte J, Crissien E, Suarez D, García R. Predictors of perceived barriers to physical activity in the general adult population: a cross-sectional study.
Braz J Phys Ther. 2017;21(1):44–50.
7. Adamsen L, Morten Q, Andersen C, et al. Effect of a multimodal high intensity
exercise intervention in
cancer patients undergoing chemotherapy: randomized controlled tri.
BMJ. 2009;339:b3410. https://doi.org/10.1136/bmj.b3410.
8. Klika RJ, Callahan KE, Drum SN. Effects of individualized 12 weeks
exercise training enhance aerobic capacity of
cancer survivors.
Phys Sportsmed. 2009;37:68–77.
9. van Waart H, Stuiverm MM, van Harten WH, et al. Effect of low-intensity physical activity and moderate—to high-intensity physical
exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial.
JCO. 2014;59:1081–109.
10. Edvardsen E, Skjønsberg OH, Holme I, Nordsletten L, Borchsenius F, Anderssen SA. High-intensity training following lung
cancer surgery: a randomised controlled trial.
Thorax. 2015;70(3):244–50.
11. Heinrich KM, Becker C, Carlisle T, et al. High-intensity functional training improves functional movement and body composition among
cancer survivors: a pilot study.
Eur J Cancer Care. 2015;24:812–7.
12. Schmitt J, Lindner N, Reuss-Borst M, Holmberg HC, Sperlich B. A 3-week multimodal intervention involving high-intensity
interval training in female
cancer survivors: a randomized controlled trial.
Physiol Rep. 2016 Feb;4(3):e12693. doi:10.14814/phy2.12693.
13. Toohey K, Pumpa KL, Arnolda L, et al. A pilot study examining the effects of low-volume high-intensity
interval training and continuous low to moderate intensity training on quality of life, functional capacity and cardiovascular risk factors in
cancer survivors.
Peer J. 2016 Oct 20;4:e2613. doi:10.7717/peerj.2613.
14. Adams SC, DeLorey DS, Davenport MH, et al. Effects of high-intensity aerobic
interval training on cardiovascular disease risk in testicular
cancer survivors: a phase 2 randomized controlled trial.
Cancer. 2017;123:4057–65.
15. Mijwel S, Backman M, Bolam KA, et al. Adding high-intensity
interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast
cancer: the OptiTrain randomized controlled trial.
Breast Cancer Res Treat. 2017;168(1):79–93.
16. Kampshoff CS, Dongen JM, Mechelen W, et al. Long-term effectiveness and cost effectiveness of high versus low-to-moderate intensity resistance and endurance
exercise interventions among
cancer survivors.
J Cancer Surviv. 2018;1–13.
17. Lee K, Kang I, Mack WJ, et al. Feasibility of high intensity
interval training in patients with breast
cancer undergoing anthracycline chemotherapy: a randomized pilot trial.
BMC Cancer. 2019;19(1):653.
18. Devin JL, Sax AT, Hughes GI, et al. The influence of high-intensity compared with moderate intensity
exercise training on
cardiorespiratory fitness and body composition in colorectal
cancer survivors: a randomized controlled trial.
J Cancer Surviv. 2016;10:467–79.
19. McNeely ML, Peddle CJ, Parliament M, Courneya KS.
Cancer rehabilitation: recommendations for integrating
exercise programming in the clinical practice setting.
Curr Canc Ther Rev. 2006;2:351–60.
20. Schmitz KH, Campbell AM, Stuiver MM, et al.
Exercise is medicine in oncology: engaging clinicians to help patients move through
cancer.
CA Cancer J Clin. 2019;69:468–84.
21. Stefani L, Galanti G, Klika R. Clinical implementation of
exercise guidelines for
cancer patients: adaptation of ACSM’s guidelines to the Italian model.
J Funct Morphol Kinesiol. 2017;2:4–21.
22. Lakoski SG, Willis L, Barlow CE, et al. Midlife
cardiorespiratory fitness, incident
cancer, and
survival after
cancer in men: the cooper center longitudinal study.
JAMA Oncol. 2015;1:231–7.
23. American College of Sports Medicine.
ACSM’s Guidelines for Exercise Testing and Prescription. 11th ed. Baltimore (MD): Wolters Kluwer; 2021.
24. Licker M, Karenovics W, Diaper J, et al. Short-term preoperative high-intensity
interval training in patients awaiting lung
cancer surgery: a randomized controlled trial.
J Thorac Oncol. 2016;1–30.